Thomas Joseph Weber, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 303 Baker House, Durham, NC 27710
Phone (919) 668-1367
Email address thomas.weber2@duke.edu

Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.

Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.

Education and Training

  • Fellow in Endocrinology, Medicine, Duke University, 1993 - 1997
  • Instructor, Medicine, Yale University, 1992 - 1993
  • Medical Resident, Medicine, Yale University, 1989 - 1992
  • M.D., University of Chicago, 1989

Publications

Kim-Chang, Julie J., Lorena Wilson, Cliburn Chan, Bernard Fischer, Guglielmo Venturi, Maureen M. Goodenow, Grace Aldrovandi, Thomas J. Weber, John W. Sleasman, and John W. Adolescent Medicine Trials Network for HIV/AIDS Interventions. “Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy..” Aids Res Hum Retroviruses, June 27, 2019. https://doi.org/10.1089/AID.2018.0270.

PMID
31115244
Full Text

Portale, Anthony A., Thomas O. Carpenter, Maria Luisa Brandi, Karine Briot, Hae Ii Cheong, Martine Cohen-Solal, Rachel Crowley, et al. “Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period..” Calcif Tissue Int, June 4, 2019. https://doi.org/10.1007/s00223-019-00568-3.

PMID
31165191
Full Text

De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl L. Insogna, Rajiv Kumar, Frank Rauch, et al. “Burosumab Improved Serum Phosphorus, Osteomalacia, Mobility, and Fatigue in the 48-Week, Phase 2 Study in Adults with Tumor-induced Osteomalacia Syndrome.” In Journal of Bone and Mineral Research, 33:50–50. WILEY, 2018.

Scholars@Duke

Insogna, Karl L., Karine Briot, Erik A. Imel, Peter Kamenický, Mary D. Ruppe, Anthony A. Portale, Thomas Weber, et al. “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis..” J Bone Miner Res 33, no. 8 (August 2018): 1383–93. https://doi.org/10.1002/jbmr.3475.

PMID
29947083
Full Text

De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Mary D. Ruppe, Karl Insogna, Diana Luca, Christina Theodore-Oklota, Javier San Martin, and Thomas Carpenter. “Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)..” In Journal of Bone and Mineral Research, 32:S280–S280. WILEY, 2017.

Scholars@Duke

Weber, Thomas J., James Koh, Samantha M. Thomas, Joyce A. Hogue, Randall P. Scheri, Sanziana A. Roman, and Julie A. Sosa. “Impaired calcium sensing distinguishes primary hyperparathyroidism (PHPT) patients with low bone mineral density..” Metabolism 74 (September 2017): 22–31. https://doi.org/10.1016/j.metabol.2017.06.004.

PMID
28764845
Full Text

Mori, Mari, Stephanie L. DeArmey, Thomas J. Weber, and Priya S. Kishnani. “Case series: Odontohypophosphatasia or missed diagnosis of childhood/adult-onset hypophosphatasia? - Call for a long-term follow-up of premature loss of primary teeth..” Bone Rep 5 (December 2016): 228–32. https://doi.org/10.1016/j.bonr.2016.08.004.

PMID
28580391
Full Text

Ruppe, Mary D., Xiaoping Zhang, Erik A. Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, et al. “Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia..” Bone Rep 5 (December 2016): 158–62. https://doi.org/10.1016/j.bonr.2016.05.004.

PMID
28326356
Full Text

Weber, Thomas J., Eileen K. Sawyer, Scott Moseley, Tatjana Odrljin, and Priya S. Kishnani. “Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys..” Metabolism 65, no. 10 (October 2016): 1522–30. https://doi.org/10.1016/j.metabol.2016.07.006.

PMID
27621187
Full Text

Weber, Thomas J. “Battle of the sex steroids in the male skeleton: and the winner is.....” J Clin Invest 126, no. 3 (March 1, 2016): 829–32. https://doi.org/10.1172/JCI85006.

PMID
26901810
Full Text

Pages